<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HB3FF53E86A3C44B39BA5392CC54D3636" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 2335 IH: Stop Tampering of Prescription Pills Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-05-14</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2335</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150514">May 14, 2015</action-date>
			<action-desc><sponsor name-id="K000375">Mr. Keating</sponsor> (for himself, <cosponsor name-id="R000395">Mr. Rogers of Kentucky</cosponsor>, <cosponsor name-id="R000583">Mr. Rooney of Florida</cosponsor>, <cosponsor name-id="L000562">Mr. Lynch</cosponsor>, <cosponsor name-id="A000055">Mr. Aderholt</cosponsor>, <cosponsor name-id="B001260">Mr. Buchanan</cosponsor>, <cosponsor name-id="K000379">Mr. Kennedy</cosponsor>, <cosponsor name-id="M000312">Mr. McGovern</cosponsor>, and <cosponsor name-id="S001145">Ms. Schakowsky</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act to incentivize the development of abuse-deterrent
			 drugs.</official-title>
	</form>
	<legis-body id="H8CB6CEE042A2439A8887C30DD9284E59" style="OLC">
 <section id="H33F5C087C1EF45E6B189F6D5C097A7D7" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Stop Tampering of Prescription Pills Act of 2015</short-title></quote>.</text> </section><section id="HDACA727B4AC2437F9548990A558B6D10"><enum>2.</enum><header>Abuse-deterrent technology</header> <subsection id="HA1AFE701A6B242348EED4569B4DFCA27"><enum>(a)</enum><header>Definition</header><text>Section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>) is amended by adding at the end the following:</text>
				<quoted-block id="H780EC13C3D1C42B78C6DF184CAD6C8F4" style="OLC">
 <subsection id="HCE9505516A5D4956A59324A4823534C3"><enum>(ss)</enum><text>The term <quote>abuse-deterrent drug</quote> means a drug that—</text> <paragraph id="H6A75EAED50B84F8682B808E91D653A6B"><enum>(1)</enum><text>contains as an active moiety a controlled substance that has been classified as opium, an opiate, or a derivative thereof, as such terms are defined or used in section 102 of the Controlled Substances Act;</text>
 </paragraph><paragraph id="H9330B2A945104D2A8E7D505944473E7E"><enum>(2)</enum><text>has been formulated for oral administration; and</text> </paragraph><paragraph id="HD0B8342DE91C40EF9A6F4E413754DCFE"><enum>(3)</enum> <subparagraph commented="no" display-inline="yes-display-inline" id="HD49707B794CE4E74ADE9A089DF478889"><enum>(A)</enum><text>exhibits physicochemical properties (demonstrated by in vitro, in vivo, or other testing, or some combination thereof, as determined appropriate by the Secretary) that make product manipulation significantly more difficult or ineffective in altering the characteristics of the drug for purposes of misuse or abuse when compared to drugs without such properties; or</text>
 </subparagraph><subparagraph id="H0C07426546734497B0D24EC8BBE3DC9E" indent="up1"><enum>(B)</enum><text>contains one or more additional active or inactive ingredients that are intended to deter abuse through potential pharmacological effects, the effectiveness of which has been demonstrated by at least one adequate and well-controlled investigation.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="HE51B865A466C458690604A3D6E462070"><enum>(b)</enum><header>Required information in application for approval of brand name drugs</header><text>Section 505(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)</external-xref>) is amended by adding at the end the following:</text>
				<quoted-block id="H6E7E5BC5D59C4AEF9579A55F95526B6F" style="OLC">
 <paragraph id="HB911129C809941B090F0B3677D9CAA8A"><enum>(7)</enum><header>Abuse-deterrent drugs</header><text>If an application submitted under this subsection is potentially subject to refusal under subsection (d)(7), the application shall include such information as the Secretary determines necessary to demonstrate that the application is not subject to such refusal.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="HB8B0FAC0462A40A3B9832C418F9C5B7A"><enum>(c)</enum><header>Approval of new brand name drugs</header><text>Section 505(d) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(d)</external-xref>) is amended—</text> <paragraph id="H69CC2C841ADF48BBBE10B0689B431D73"><enum>(1)</enum><text>by inserting <quote>(7)(A) such drug has been formulated for oral administration; (B) such drug contains as an active moiety a controlled substance that has been classified as opium, an opiate, or a derivative thereof, as such terms are defined or used in section 102 of the Controlled Substances Act; (C) such drug is not an abuse-deterrent drug; and (D) the Secretary has previously approved pursuant to an application submitted under subsection (b) or (j) a drug that (i) contains the same active moiety; (ii) is an abuse-deterrent drug, and (iii) has not been discontinued from marketing; or</quote> after <quote>(6) the application failed to contain the patent information prescribed by subsection (b); or</quote>;</text>
 </paragraph><paragraph id="HCD28F5F8BD1B45369216C418A5F68E29"><enum>(2)</enum><text>by striking <quote>(7) based on fair</quote> and inserting <quote>(8) based on fair</quote>;</text> </paragraph><paragraph id="H232601E087B14FB6926F24A27E7B81FE"><enum>(3)</enum><text>by striking <quote>clauses (1) through (6)</quote> and inserting <quote>paragraphs (1) through (7)</quote>; and</text>
 </paragraph><paragraph id="H7B217F3CCE7140FDB78AC532927CA9E3"><enum>(4)</enum><text>by inserting <quote>The Secretary may issue an order approving an application, even if paragraph (7) applies, upon a finding that paragraphs (1) through (6) and paragraph (8) do not apply and that such approval is necessary either to prevent or alleviate a drug shortage or to otherwise address a significant unmet public health need.</quote> before <quote>As used in this subsection and subsection (e)</quote>.</text>
 </paragraph></subsection><subsection id="H417DF4026EDE41CA9EF6E2F3EE2365D6"><enum>(d)</enum><header>Generic drugs</header><text>Section 505(j) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>) is amended—</text> <paragraph id="HE1FD03A6FC004A9E9EA2E803043E2C8E"><enum>(1)</enum><text>in paragraph (2)—</text>
 <subparagraph id="HE2E682C2AF834877ACFEE331D2CA1794"><enum>(A)</enum><text>subparagraph (A)—</text> <clause id="H17E3B2FA76DE477A89A5DBAD5514DB6F"><enum>(i)</enum><text>in clause (vii), by striking <quote>and</quote> at the end;</text>
 </clause><clause id="H3C5A4DF4C4704BCC9C03A15FE1FCC9F3"><enum>(ii)</enum><text>in clause (viii), by striking the period at the end and inserting <quote>; and</quote>;</text> </clause><clause id="HC7A59DC5A38F47B7B52304CB9C9F7381"><enum>(iii)</enum><text>by inserting after clause (viii) the following:</text>
							<quoted-block id="HDE4F34237B154B908959AE5E4B76F4F1" style="OLC">
 <clause id="HFB5C6AE4878D42B08BE10B50338EA35F" indent="up1"><enum>(ix)</enum><text>if the listed drug is an abuse-deterrent drug due to its physicochemical properties, information from comparative in vitro, in vivo, or other testing, or some combination thereof, as appropriate based on the type of data submitted for the listed drug, that demonstrates the new drug resists manipulation or the effect of manipulation to a degree at least comparable to the listed drug.</text></clause><after-quoted-block>; and</after-quoted-block></quoted-block>
 </clause><clause id="H0F02123585164B0F8F7CE437C6706156"><enum>(iv)</enum><text>in the continuation text at the end of the subparagraph, by striking <quote>clauses (i) through (viii)</quote> and inserting <quote>clauses (i) through (ix)</quote>;</text> </clause></subparagraph><subparagraph id="HC8378E1A2E124D53A9704C581ADCB166"><enum>(B)</enum><text>in subparagraph (C)—</text>
 <clause id="H50BCA82608D04CFAB92FEFD0F9E79EB9"><enum>(i)</enum><text>in clause (i), by striking <quote>or</quote> at the end;</text> </clause><clause id="HC87471752C8F470FACB6E11E5DADDCFD"><enum>(ii)</enum><text>in clause (ii), by striking the period at the end and inserting <quote>; or</quote>; and</text>
 </clause><clause id="HEDB70F2CD42343B384690509A7D13D76"><enum>(iii)</enum><text>by adding at the end the following:</text> <quoted-block id="H0B4A06C733274E12A4A4517FD8DE879C" style="OLC"> <clause id="H23BE472D0BA847DDA9F3FD1E751BB1DB" indent="up1"><enum>(iii)</enum><text>that the listed drug is an abuse-deterrent drug and one or more of the new drug’s active moieties differ in any material respect (in amount or otherwise) from those of the listed drug.</text></clause><after-quoted-block>;</after-quoted-block></quoted-block>
 </clause></subparagraph></paragraph><paragraph id="H7249FFB64A0B456D87C35903550A5CC1"><enum>(2)</enum><text>in paragraph (5), by adding at the end the following:</text> <quoted-block id="H0B8E30AA84154024867E8C3825E7D6A1" style="OLC"> <subparagraph id="H6A94442F5334403CB20C5B7D7A54F3B5" indent="up1"><enum>(G)</enum><text>If a drug has been approved pursuant to an application submitted under paragraph (2), and thereafter the listed drug referred to in the application becomes an abuse-deterrent drug, the drug so approved shall not be considered to be bioequivalent to, or to have the same therapeutic effect as, the listed drug (as described in paragraph (2)(A)(iv)) unless and until the drug so approved has been found by the Secretary to meet the requirements of paragraph (2)(A)(ix).</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </paragraph><paragraph id="H80E57840A26E4D169671A4A52AF5D45C"><enum>(3)</enum><text>in paragraph (6)—</text> <subparagraph id="H3A3764231C6341EB9D73326BC5D01166"><enum>(A)</enum><text>by striking <quote>(6) If a drug</quote> and inserting <quote>(6)(A) If a drug</quote>;</text>
 </subparagraph><subparagraph id="H8EA51E0E74F249FBB2F7BE8381D774A1"><enum>(B)</enum><text>by striking <quote>(A) for the</quote> and inserting <quote>(i) for the</quote>;</text> </subparagraph><subparagraph id="H8D37EDB1ECDC4269A78F50C7F872AF28"><enum>(C)</enum><text>by striking <quote>(B) if the</quote> and inserting <quote>(ii) if the</quote>; and</text>
 </subparagraph><subparagraph id="H7709C551E94B4722B9B6E9BF1E992AA7"><enum>(D)</enum><text>by adding at the end the following:</text> <quoted-block id="H1AD19451B1C748A0BE57845FCD2AF41A" style="OLC"> <subparagraph id="HE98C04A9F1F140CCA2C0EE6E28260895" indent="up1"><enum>(B)</enum><text>For purposes of this paragraph and paragraph (7)(C), a withdrawal or suspension of a drug formulated for oral administration shall be considered to have been for safety or effectiveness reasons if—</text>
 <clause id="H95FBB9828F8E466F83CC3C2F195E8477"><enum>(i)</enum><text>the approval of a listed drug, which is not an abuse-deterrent drug, is withdrawn or suspended, or a listed drug, which is not an abuse-deterrent drug, is withdrawn from sale; and</text>
 </clause><clause id="H2769C1ADD02142A09761C947765C92FE"><enum>(ii)</enum><text>the Secretary has previously approved pursuant to an application under subsection (b) a drug that—</text> <subclause id="HACAC88AF50A94B2BAE5BC2DB4C263CA1"><enum>(I)</enum><text>is in the same dosage form;</text>
 </subclause><subclause id="H5F17C1CC3FC84A948243A8F1645DE92A"><enum>(II)</enum><text>contains the same controlled substance as an active moiety;</text> </subclause><subclause id="H0EFFD814554C4C93A0E218986E39E371"><enum>(III)</enum><text>is an abuse-deterrent drug; and</text>
 </subclause><subclause id="HE2FF8BB0207145389B3EF1D5CC51CA93"><enum>(IV)</enum><text>has not been discontinued from marketing.</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block> </subparagraph></paragraph></subsection><subsection id="H1BE44FFFDE9145E0952C0328BDB479D0"><enum>(e)</enum><header>Withdrawal of previously approved brand name and generic drugs</header><text>Section 505(e) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(e)</external-xref>) is amended—</text>
 <paragraph id="HC02E3EBBB24443B8ABE4B8AFCA37EEDA"><enum>(1)</enum><text>by inserting <quote>or (6)(A) the drug contains as an active moiety a controlled substance that has been classified as opium, an opiate, or a derivative thereof, as such terms are defined or used in section 102 of the Controlled Substances Act; (B) the drug is formulated for oral administration; (C) the drug is not an abuse-deterrent drug; and (D) the Secretary has previously approved pursuant to an application submitted under subsection (b) or (j) a drug that contains the same active moiety, is an abuse-deterrent drug, and has not been discontinued from marketing</quote> before <quote>: <italic>Provided</italic>,</quote>; and</text>
 </paragraph><paragraph id="H02475CC931954B679CB00928EA262181"><enum>(2)</enum><text>by adding at the end the following: <quote>The Secretary may waive the application of paragraph (6) of the first sentence of this subsection in the case of a drug intended for use in a special needs population. In withdrawing (under paragraph (6) of the first sentence of this subsection) the approval of an application with respect to any drug, the Secretary shall, on a case-by-case basis, delay the effective date of such withdrawal for a period deemed sufficient by the Secretary to give the sponsor an opportunity to obtain approval under this section for a formulation of the drug meeting the criteria described in paragraph (2) of the definition of a </quote>abuse-deterrent drug<quote> in section 201(ss).</quote>.</text>
 </paragraph></subsection><subsection id="H973DA52141E3490E91CFB8E1E4AF14EB"><enum>(f)</enum><header>Listed drugs</header><text>Section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(7)</external-xref>) is amended by adding at the end the following:</text>
				<quoted-block id="H2B387E477E574D4592418F22F1AE1B09" style="OLC">
 <subparagraph id="H074245379058437685AF9451BBD6A0B6" indent="up1"><enum>(D)</enum><text>Beginning 60 days after the date of the enactment of the <short-title>Stop Tampering of Prescription Pills Act of 2015</short-title>, the Secretary shall—</text> <clause id="H60D80D934540494A9FD3EB8A1F03494F"><enum>(i)</enum><text>include in the list under subparagraph (A) a list of each drug or category of drugs which the Secretary has found to be abuse-deterrent drugs; and</text>
 </clause><clause id="HF1CF23CAAC7C415CB7CB676532761309"><enum>(ii)</enum><text>update the list under subparagraph (A)—</text> <subclause id="H37F108D4B6CE4D409F90D854BA7CE6E5"><enum>(I)</enum><text>to remove from the list of abuse-deterrent drugs any drug the Secretary later determines is not an abuse-deterrent drug; and</text>
 </subclause><subclause id="HEA9C359926B44338890AB5A6ED1C19DC"><enum>(II)</enum><text>as required by subparagraph (C) to reflect the application of paragraph (6)(B) to drugs that are withdrawn or suspended.</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection></section></legis-body>
</bill>


